Position in INSM
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,796,227
+$1,153,223 QoQ
Shares Held
16,847
+277.3% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.49%
of 13F equity value
Holder Rank
#293
of 663 holders
Holding Since
Sep 2020
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in INSM Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Aigen Investment Management, LP holds $12,762,383 across 22 Biotechnology names. INSM ranks #3 (14.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,452 | $3,701,631 | |
| 2 | INCY |
Incyte Corp
|
23,563 | $2,671,101 | |
| 3 | INSM |
INSMED Inc
This page
|
16,847 | $1,796,227 | |
| 4 | ASND |
Ascendis Pharma A/S
|
4,073 | $1,086,350 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
2,390 | $585,000 | |
| 6 | SMMT |
Summit Therapeutics Inc.
|
24,477 | $356,629 | |
| 7 | JANX |
Janux Therapeutics, Inc.
|
22,841 | $350,837 | |
| 8 | XENE |
Xenon Pharmaceuticals Inc.
|
5,218 | $314,958 |
All Filings in INSM
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,796,227 | 16,847 | Shares | Sole | 2026-08-14 | |
| 2025-09-30 | $643,004 | 4,465 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,606,315 | 15,961 | Shares | Sole | 2025-08-12 | |
| 2024-12-31 | $824,061 | 11,936 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $297,037 | 4,069 | Shares | Sole | 2024-11-05 | |
| 2022-12-31 | $362,177 | 18,127 | Shares | Sole | 2023-02-10 | |
| 2022-03-31 | $428,123 | 18,218 | Shares | Sole | 2022-05-05 | |
| 2020-12-31 | $246,379 | 7,401 | Shares | Sole | 2021-02-12 | |
| 2020-09-30 | $349,040 | 10,860 | Shares | Sole | 2020-11-06 | |
| No filing history on record for this holder in this stock. | ||||||